ArticleNature communications2024
Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Differentially private federated learning for localized control of infectious disease dynamics.Scientific reports · 2026Article
- SARS CoV-2 seroprevalence and rising antibody titres across successive pandemic waves in accra, Ghana: August 2020 to January 2022.Scientific reports · 2026Article
- Participant recruitment and retention in a longitudinal study: experience from SARS-CoV-2 cohort in Ethiopia.BMC medical research methodology · 2026Observational
- SARS-CoV-2 neutralising antibody profiles reveal variant specific antibody dynamics and regional differences in infection histories in Malawi.PLOS global public health · 2026Article
- Assessing COVID-19 Vaccination Uptake and Incident Infections Among Ethiopian Healthcare Workers, Addis Ababa-2022: Implications for Public Health Preparedness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Monitoring SARS-CoV-2 variants in wastewater during periods of low clinical case surveillance in Ethiopia.mSphere · 2025Article
- Article
- Distinct proteomic signatures in Ethiopians predict acute and long-term sequelae of COVID-19.Frontiers in immunology · 2025Article
- Molecular and seroepidemiology of SARS-CoV-2 among influenza-like illness and severe Acute respiratory illness cases in selected health facilities in Ethiopia.Frontiers in public health · 2025Article
- Clinical profiles and mortality predictors of hospitalized patients with COVID-19 in Ethiopia.BMC infectious diseases · 2024Article
- Tailoring COVID-19 Vaccination Strategies in High-Seroprevalence Settings: Insights from Ethiopia.Vaccines · 2024Article
- Longitudinal wastewater-based surveillance of SARS-CoV-2 during 2023 in Ethiopia.Frontiers in public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Under-reporting of COVID-19 and the limited information about circulating SARS-CoV-2 variants remain major challenges for many African countries. We analyzed SARS-CoV-2 infection dynamics in Addis Ababa and Jimma, Ethiopia, focusing on reinfection, immunity, and vaccination effects. We conducted an antibody serology study spanning August 2020 to July 2022 with five rounds of data collection across a population of 4723, sequenced PCR-test positive samples, used available test positivity rates, and constructed two mathematical models integrating this data. A multivariant model explores variant dynamics identifying wildtype, alpha, delta, and omicron BA.4/5 as key variants in the study population, and cross-immunity between variants, revealing risk reductions between 24% and 69%. An antibody-level model predicts slow decay leading to sustained high antibody levels. Retrospectively, increased early vaccination might have substantially reduced infections during the delta and omicron waves in the considered group of individuals, though further vaccination now seems less impactful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.